In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 201 to 225 of 384

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance	3 September 2026
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
MMprofiler for estimating risk in newly diagnosed multiple myeloma	HealthTech guidance	6 May 2027
Monofocal intraocular lenses for cataract surgery	HealthTech guidance	10 March 2027
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]	Technology appraisal guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Multidisciplinary care of children and young people with achondroplasia	NICE review	29 April 2026
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	TBC
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance	9 September 2026
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance	TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neurostimulation of lumbar multifidus for refractory chronic low back pain with lumbar multifidus dysfunction	HealthTech guidance	TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	4 September 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]	Technology appraisal guidance	TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance	TBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance	11 November 2026
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]	Technology appraisal guidance	TBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance	14 October 2026

Results per page

10
25
50
All